Nanobiotix S.A. (NBTX)

Market Cap	178.35M
Revenue (ttm)	45.22M
Net Income (ttm)	-35.87M
Shares Out	47.40M
EPS (ttm)	-0.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,656
Open	3.780
Previous Close	3.780
Day's Range	3.573 - 4.110
52-Week Range	3.573 - 8.960
Beta	1.40
Analysts	Strong Buy
Price Target	11.50 (+182.66%)
Earnings Date	Nov 26, 2024

About NBTX

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: NBTX
• Website: https://www.nanobiotix.com

Financial Performance

In 2023, Nanobiotix's revenue was 36.21 million, an increase of 658.12% compared to the previous year's 4.78 million. Losses were -39.70 million, -30.40% less than in 2022.

Financial numbers in EUR

Analyst Forecast

According to 2 analysts, the average rating for NBTX stock is "Strong Buy." The 12-month stock price forecast is $11.5, which is an increase of 182.66% from the latest price.

Price Target

$11.5

(182.66% upside)

Analyst Consensus: Strong Buy